Key highlights:

• XRF Scientific agreed to acquire Bruker's combustion gas analysis (CGA) business for US$4 million upfront plus up to US$1 million earnout, representing approximately 0.75 times the unit's 2025 unaudited revenue of roughly US$5.3 million.

• The CGA line adds four instruments measuring carbon, sulphur, oxygen, hydrogen and nitrogen, extending XRF's reach from mining laboratories into nuclear energy, rare earths, steel, cement and powder metallurgy markets.

• FY2025 net profit after tax rose 17% to A$10.4 million despite flat revenue, the fully franked dividend was lifted 15% to 4.5 cents, and the group held net cash of A$12.2 million at year-end.

For most of its life on the ASX, XRF Scientific (ASX:XRF) has been quietly indispensable rather than headline-grabbing, making the fluxes, fused beads and precision instruments that laboratories rely on to work out what is in a rock, a metal or a bag of cement. So when the Perth-based small cap announced in April 2026 that it was buying Bruker's combustion gas analysis business, the market took notice: this was XRF stepping outside its comfort zone.

The deal is small in dollar terms but telling in intent: it signals a company that wants a broader seat at the analytical instruments table, not merely the go-to name in sample preparation. For shareholders who have watched XRF compound earnings for years, the question is whether this is disciplined expansion or a distraction.

Company Overview

XRF Scientific Limited is a Perth-headquartered manufacturer of precious metal products and analytical equipment used in materials testing. It sits at the unseen front end of the resources value chain: before an assay lab can tell a miner its ore grade, a sample must first be fused and measured on XRF's chemistry and machines.

The group reports across three divisions. Consumables makes the flux products that fuse samples into glass discs ready for X-ray fluorescence analysis. Precious Metals fabricates platinum labware and recovers precious metals used in that process. Capital Equipment builds fusion machines, furnaces and instruments, and includes the Orbis Mining automation business. Together they give XRF both recurring consumables income and lumpier equipment sales across Australia, Europe and beyond.

Latest News

On 23 April 2026 XRF told the market it had agreed to acquire the combustion gas analysis (CGA) business of Bruker AXS SE, part of the global instruments group Bruker. The price is modest: US$4 million upfront from existing cash, plus an earnout of up to US$1 million based on 7% of net CGA revenue over three years. That is about 0.75 times the unit's 2025 unaudited revenue of roughly US$5.3 million.

The CGA line comprises four instruments that measure elements such as carbon, sulphur, oxygen, hydrogen and nitrogen. Crucially, its end-markets stretch well beyond mining into nuclear energy, rare earths, powder metallurgy, steel and cement manufacturing. XRF plans to transfer production from Germany to Perth during the third quarter of 2026, with revenue expected in the fourth, and managing director Vance Stazzonelli called the deal an exciting expansion of the group's instrument range.

Why Investors Are Watching

XRF has become a favourite among Australian small-cap investors precisely because it looks nothing like a speculative one. It converts profit into cash, carries almost no debt, pays a growing fully franked dividend and has repeatedly bought bolt-on businesses at sensible prices. By mid-2026 the shares had climbed to around A$2.85, valuing the company at roughly A$400 million.

The CGA acquisition tests whether XRF can keep finding value-accretive deals as it grows. Paid under one times revenue and funded entirely from cash, it is exactly the disciplined capital allocation the market has come to expect.

Growth Opportunities

The clearest opportunity is cross-selling. XRF already sells into thousands of laboratories worldwide, and the CGA instruments give its sales force a new product to place with existing customers while opening doors in under-served industries, from nuclear and rare earths to advanced manufacturing.

Relocating manufacturing to Perth should also let XRF apply its own margin discipline to the line. Beneath that sit established growth engines - rising consumables volumes, the Orbis automation push and steady European expansion - the kind of incremental, self-funded growth that has defined XRF's record.

Risks

Integration is the near-term risk. Moving instrument production from Germany to Perth is not trivial, and any slippage could push out the expected fourth-quarter 2026 revenue start or add cost. The acquired revenue figure is also unaudited.

More broadly, XRF remains tied to the health of the global mining sector; a downturn in exploration and production spending would weigh on consumables demand and delay equipment orders. It also carries currency exposure across the Australian dollar, euro and US dollar, and flat headline revenue in FY2025 shows top-line growth is not guaranteed even when profits improve.

Industry Outlook

The structural backdrop for analytical instruments remains supportive. Miners are chasing lower-grade, more complex orebodies that demand more testing, and the energy transition is driving fresh demand for accurate measurement of battery metals, rare earths and specialty materials.

Combustion gas analysis fits neatly into that trend, giving XRF exposure to end-markets such as nuclear energy and powder metallurgy that are expanding largely independently of the mining cycle.

What to Watch Next

The immediate milestones are operational: confirmation that the CGA transfer to Perth is on schedule and that revenue begins in the fourth quarter of 2026 as guided. The FY2026 full-year result, due in August 2026, will show whether the strong momentum held.

Beyond that, watch how quickly the CGA line becomes earnings-accretive, whether cross-selling turns into orders, and whether management deploys cash into further bolt-on deals.

Conclusion

XRF's move into combustion gas analysis is a small, disciplined deal - cheap, cash-funded and bolted onto an existing network - that nudges the company into new industries and away from pure reliance on the mining laboratory.

The execution risk around the Perth transfer is real, and the resources cycle still casts a shadow over demand. But with a strong balance sheet, a rising dividend and a proven habit of buying well, XRF has earned the benefit of the doubt. This article is general information, not investment advice, and readers should do their own research or seek professional guidance before acting.